Back to results
US 7,641,908 B2Granted
Dengue serotype 2 attenuated strain
AssigneesSanofi Pasteur Limited, Center for Disease Control and Prevention
InventorsRichard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
Life of this patent
Estimating the term…
Abstract
The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells. The invention further relates to a vaccine composition which comprises a VDV2 strain.
Claims10
A live attenuated dengue-2 virus strain which comprises sequence SEQ ID NO:
- 38 wherein at least nucleotides at positions 736, 1619, 4723, 5062, 9191, 10063, and 10507, are mutated, with the proviso that the following nucleotides are not mutated:
- 57, 524, 2055, 2579, 4018, 5547, 6599, and 8571.
An immunogenic composition comprising a live attenuated dengue-2 virus strain which comprises sequence SEQ ID NO:
- 38 wherein at least nucleotides at positions 736, 1619, 4723, 5062, 9191, 10063, and 10507, are mutated, with the proviso that the following nucleotides are not mutated:
- 57, 524, 2055, 2579, 4018, 5547, 6599, and 8571, in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.